製薬会社の代表と内科のレジデントとの接触制限が,研修後の態度や行動に与える影響
B B McCormick1, G Tomlinson, P Brill-Edwards
1Mount Sinai Hospital, 600 University Ave, Room 427, Toronto, Ontario, Canada M5G 1X5.
JAMA
|November 3, 2001
まとめ
内部医学研修中に製薬会社代表 (PCR) を制限する政策は,PCR情報から医師の利益が認識され,在留後の接触が減少しました. これは,訓練政策が医師と医薬品の相互作用に大きな影響を与えることを示唆しています.
科学分野:
- 医療教育 医療教育について
- 保健政策 保健政策 保健政策
- 医薬品のマーケティング
背景:
- 医療従事者および製薬会社の代表者 (PCRs) の間の相互作用を制限する政策が,医師の長期的な態度と行動に与える影響は十分に理解されていません.
- マクマスター大学は1992年に規制政策を導入したが,トロント大学はそのような政策を導入しなかった.
研究 の 目的:
- 内科研修中にPCR接触に関する制限政策が,研修終了後数年の医師の態度や行動を予測するかどうかを調査する.
- 研修中のPCR接触の頻度と,その後の医師の診療パターンの間の相関を評価する.
主な方法:
- トロント大学の研修生,McMasterの政策前研修生,McMasterの政策後の研修生という3つの医師コホートで,遡及的な調査分析が行われました.
- 調査では,PCR情報の有用性に対する医師の態度と,診療所訪問や接触頻度 (贈り物,手数料,コンサルティング料金) を含む行動が評価されました.
主要な成果:
- 政策後のマクマスター政策の下で訓練された医師は,トロントと政策前のマクマスター研修生と比較して,PCR情報を有益であると認識する可能性が低い.
- オフィス訪問の割合はグループごとに似ていたが,McMasterの政策後の研修生は,PCRとの接触の総頻度が低いと報告した.
- 研修中のPCR接触の増加は,PCR情報と研修後のより高い接触頻度の認識された利益を肯定的に予測しました.
結論:
- 住人のPCRとの接触を制限する政策は,医薬品の相互作用に関する医師の将来の態度と行動に影響を与えるようです.
- 医療訓練中に医師と製薬会社の代表者との接触の頻度は,後の実践に関連する態度と行動の重要な予測因子です.
関連する概念動画
01:08Obedience
26.2K
According to obedience research, we may harm others under the forceful pressures of an authority figure (Milgram, 1974). How about if the inappropriate orders were delivered with less force? The increasing interdependence between nurses and physicians compelled Hofling and his colleagues to explore nurses’ reactions to a potentially harmful medical request made by the perceived authority figure, the doctor (Hofling, Brotzman, Dalrymple, Graves, & Pierce, 1966). In this situation,...
26.2K
01:03Drug Control Governance: Regulatory Bodies and Their Impact
706
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
706
01:26FDA Approved Drugs: Changes to Approved Drugs
343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
01:25Pharmacokinetics: Drug–Drug Interactions
813
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
813
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
01:26Pharmaceutical Poisoning: Potential Scenarios
116
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
116